Compare NFG & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NFG | BIO |
|---|---|---|
| Founded | 1902 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Laboratory Analytical Instruments |
| Sector | Utilities | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 7.2B |
| IPO Year | 1997 | N/A |
| Metric | NFG | BIO |
|---|---|---|
| Price | $92.97 | $280.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $91.20 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 630.2K | 288.4K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | ★ 576.19 | N/A |
| EPS | ★ 1.98 | N/A |
| Revenue | ★ $2,277,541,000.00 | N/A |
| Revenue This Year | $13.10 | $2.31 |
| Revenue Next Year | $31.56 | $3.10 |
| P/E Ratio | $46.79 | ★ $9.72 |
| Revenue Growth | ★ 17.11 | N/A |
| 52 Week Low | $69.93 | $211.43 |
| 52 Week High | $94.13 | $343.12 |
| Indicator | NFG | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 77.30 | 45.91 |
| Support Level | $85.34 | $266.71 |
| Resistance Level | $94.13 | $290.01 |
| Average True Range (ATR) | 1.88 | 9.20 |
| MACD | 0.51 | 1.44 |
| Stochastic Oscillator | 96.99 | 61.55 |
National Fuel Gas Co is a diversified energy company involved in natural gas production, gathering, transportation, distribution, and marketing. It operates through three segments: Integrated Upstream and Gathering, Pipeline and Storage, and Utility. The majority of revenue comes from the Integrated Upstream and Gathering segment, which focuses on Seneca's natural gas exploration and development in the Appalachian region and Midstream operations supporting gas processing and gathering. The Pipeline and Storage segment transports and stores natural gas for customers in the northeastern United States and Canada, while the Utility segment supplies natural gas to retail customers in western New York and northwestern Pennsylvania. the company opeartes in United States.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.